Are these 2 FTSE 250 shares now unmissable buys after crashing 48%?

Harvey Jones is hunting for FTSE 250 bargains and reckons these two are ripe for a comeback after recent troubles. Dare he buy them both?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 250 contains plenty of great value stocks right now. These two have caught my eye after crashing hard. Should I snap them up before they recover?

Biotherapeutics company PureTech Health (LSE: PRTC) is popular among my fellow Fools. It’s not without risk though.

The PureTech share price has plunged 49.38% in the last three years. Over 12 months, it’s down 10.51%. The rate of descent has slowed, but not much.

Created with Highcharts 11.4.3PureTech Health Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

PureTech is all about the future. It specialises in medicines related to the brain, gut, and immune system, and is currently pushing a pipeline of 28 therapeutics through US and EU regulatory processes.

PureTech offers outsized rewards

That involves spending bags of money on R&D today in the hope of making bags more when treatments make it to market. Inevitably, it’s a bumpy process.

Recent results make painful reading with a pre-tax loss in each the last three years. 2022 full-year revenues of $15.61m plunged to just $3.33m in 2023. Despite that, it ended the year with level cash, plus cash equivalents and short-term investments of $326m. The board says that gives it an operational runway into “at least 2027”.

CEO Bharatt Chowrira has talked up the group’s track record of clinical success, which he says is “six times the industry average”. Now he needs to make money from it.

PureTech recently treated investors to a $100m share buyback, using proceeds from the $14bn sale of the PureTech-founded Karuna Therapeutics to Bristol Myers Squibb. That’s a big buyback, given the group’s market cap of £393m. Not that it’s shifted the share price much.

The price could fly if it starts making money but it’s too risky for me to buy today. I’ll watch and wait to see what its future holds.

Assura is a dividend star

Real estate investment trust (REIT) Assura (LSE: AGR) is another Foolish favourite. It builds and manages a portfolio of community healthcare buildings such as GP surgeries, which it leases to the NHS. It’s been doing this for 20 years, now.

This should be a relatively solid investment, as rents are ultimately underpinned by local authorities. However, it’s been hit by volatile property values, swinging from a full-year profit of £155.8m in 2022 to a £119.2m loss in 2023. The culprit was the surge in interest rates following former PM Liz Truss’s mini-Budget meltdown in autumn 2022. 

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice.

The Assura share price has crashed 46.4% over three years and is down 5.5% over 12 months. It now looks decent value at 12.24 times earnings, but hardly dirt cheap.

Created with Highcharts 11.4.3Assura Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Total revenues have been rising steadily year-on-year, despite the challenging economic environment. Net rental income climbed 9% to £138m in 2023. The pace slowed to 3.8% in 2024, though, lifting net income to £143.3m.

Assura’s balance sheet remains robust with undrawn facilities and cash of £235m, marginally down from £243m a year earlier. It could get a nice boost if interest rates fall and property prices rise.

The big attraction is the dividend, with a trailing blockbuster yield of 7.87%. Better still, the company increased shareholder payouts by 5.2% in May. That’s a brilliant income at a decent price. Plus potential share price growth too. I’ll buy it when I have the cash. And keep watching PureTech.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s the dividend forecast for Rolls-Royce shares as Trump rocks the markets

Rolls-Royce shares have joined in the volatility over the past week. However, with the direction being largely downwards, the dividend…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

Dividend yields of up to 11%! Here are 3 UK passive income stocks to consider

Searching for ways to supercharge your passive income with UK dividend stocks? Here are three that have grabbed our writer's…

Read more »

Young Caucasian woman at the street withdrawing money at the ATM
Investing Articles

£10,000 invested in NatWest shares at the start of 2025 is now worth…

NatWest shares surged into 2025, but things have become a little more complicated in recent weeks. Dr James Fox explores.

Read more »

Investing For Beginners

Why the FTSE 250 could outperform the FTSE 100 for the rest of the year

Jon Smith explains why the FTSE 250 could do better than its big brother when factoring in domestic exposure and…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Tariff fears send the Lloyds share price tumbling, but the dividend yield is climbing

Just when the Lloyds Banking Group share price had been rising steadily, along comes a global upheaval to knock it…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Here’s how a stock market crash could help an investor retire years early

A stock market crash can be alarming -- but for the well-prepared investor, it can also be an exceptional opportunity…

Read more »

Investing Articles

1 key fact to remember in this stock market correction

This writer takes a look at a FTSE 100 investment trust that is catching his eye after the recent massive…

Read more »

Investing Articles

I was wrong about the Tesla stock price!

Tesla stock's been affected more than most by ‘Liberation Day’. But our writer has other concerns about Elon Musk’s company.

Read more »